Biden Seeks Coverage for GLP-1 RA Medications by Medicare, Medicaid
The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) obesity medications like semaglutide (Wegovy) and tirzepatide (Zepbound), challenging a two-decade-old law and facing probable opposition from the incoming Trump administration.
The Biden administration is proposing a major expansion of how Medicare and Medicaid cover the weight-loss drugs Wegovy and ...
The Biden administration said it would allow the program to pay for GLP-1 anti-obesity drugs, but the Trump administration ...
Weight-loss drugs like Ozempic and Zepbound would be covered by Medicare and Medicaid, giving access to millions of ...
WASHINGTON — Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback